Rakovina Therapeutics Company Description
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments based on novel series of small-molecule DNA-damage response targets.
The company’s preclinical product pipeline include kt-2000AI, an poly(ADP)-ribose polymerase (PARP) brain penetrant cancer therapy; kt-3000, a bi-functional small-molecule drug candidate; kt-3283 series for the treatment of PARP resistant adult and childhood cancers; and kt-4000, a DNA-damaging DDR inhibitors.
It has a research collaboration with Variational AI Inc. to identify and develop novel small-molecule therapies against DNA-damage response (DDR) targets for the treatment of cancer.
Additionally, it signed a letter of intent with NanoPalm Ltd. to form a joint venture to co-develop novel small-molecule oncology therapeutics.
The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Mads Daugaard |
Contact Details
Address: 999 West Broadway Vancouver, British Columbia V5Z 1K5 Canada | |
| Website | rakovinatherapeutics.com |
Stock Details
| Ticker Symbol | RKVTF |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Mads Daugaard Ph.D. | President, Chief Executive Officer and Chief Scientific Officer |
| Jeffrey A. Bacha B.Sc., M.B.A. | Executive Chairman |
| Dr. John Langlands Ph.D. | Chief Operating Officer |
| Dr. David M. Kideckel M.B.A., MBA, Ph.D. | Chief Financial Officer and Director |
| Michelle Seltenrich M.B.A., MBA | Director of Corporate Development |